Market Signal Briefing

Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients Complex modalities are WuXi Biologics' core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs Bispecific/multispecific antibodies are WuXi Biologics' most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of the company's revenue and delivers 120%+ YoY growth Scaling integrated CRDMO capabilities across the U.S. and Asia, while expanding the global network into the Middle East , /PRNewswire/ -- On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company's 2025 achievements and outlining its outlook.

Dr. Chen commented, "Through the CRDMO model, we have achieved significant advancements spanning discovery, development, and manufacturing. By executing our 'Follow and Win the Molecule' strategy, world-class quality systems, deep technical capabilities and operational excellence, WuXi Biologics has become the partner of choice for biopharmaceutical innovators and MNCs. With the launch of the CRDMO+ strategy, we will further enable client success by scaling global manufacturing capacity, advancing modality innovation, and accelerating speed and execution."

Strong Project Funnel Achieving Record High

Building on leading technology, proven execution and expanding global reach, WuXi Biologics added 209 new integrated projects in 2025, increasing the total to 945 and reinforcing its position as the partner of choice for biopharma innovators worldwide. Approximately half of the new projects originated from U.S. clients, underscoring strong client trust from the market. 

The company has excelled in three key areas—bispecific/multispecific antibodies, ADCs, and mAbs—leveraging its deep expertise and fully integrated end-to-end capabilities.

Bispecific/multispecific antibody and ADC projects continued to expand rapidly, with each growing by approximately 30% to reach 196 and 252 projects, respectively. Together, these complex modalities now account for nearly 50% of the total pipeline, underscoring strong demand for differentiated biologics. In parallel, the company maintains a deep and diversified base of over 400 mAbs and other protein therapeutics, including multiple multi-billion-dollar franchises in late-stage development and commercial manufacturing. With strength across research, development, manufacturing, bispecific/multispecific antibodies represent WuXi Biologics' most exciting, fastest-growing and highest‑margin modality, contributing nearly 20% of the company's revenue and achieving YoY growth exceeding 120%.

Through its "Win-the-Molecule" strategy, WuXi Biologics has been securing a quantity of projects across different stages. In 2025, the company added 23 projects, including 6 Phase III and commercial projects. Notably, half of these projects involve complex modalities, led by bispecific/multispecific antibodies and ADCs.

Research: Accelerating Deal Momentum and Platform Inflection

Research services maintained strong momentum from 2024 into 2025, with accelerating T‑cell engager (TCE) deals highlighting an inflection point for the company's CD3 platform.

The CD3 platform enables bispecific antibodies to retain potent tumor-killing activity against target cells while minimizing cytokine release, optimizing the efficacy-safety balance. It has been widely adopted within the industry, including Merck, GSK, Chia Tai Tianqing Pharmaceutical, and Zai Lab.

WuXi Biologics' research services business achieved another record year in 2025, securing record-breaking upfront payments and potential milestone values exceeding USD 4 billion.

Development: Pioneering Innovative Solutions

WuXi Biologics continues to expand its integrated services through new technology solutions that accelerate timelines, improve product quality and ensure scalable manufacturing.

It launched WuXia™ TrueSite, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies. The platform has achieved an average mAb titer exceeding 8.0 g/L, with over 99% of clonal cell lines maintaining stable protein expression after passaging for 60 generations.

The company has also expanded core technology solutions for high-dose delivery into clinical and commercial applications, including High-throughput formulation development platform WuXiHighTM, Hyaluronidase Co-Formulation platform, and large-volume devices capabilities.

Manufacturing: Advancing Growth at Speed and Scale

As the "Follow and Win the Molecule" strategy continues, the total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025. Manufacturing is positioned for accelerated growth, driven by an expanding commercial portfolio and revenue ramp per program over time.

Built on operational excellence, technology leadership and a proven quality system, WuXi Biologics completed 28 PPQs in 2025 and has 34 PPQs scheduled for 2026 based on current contracts, reflecting strong momentum in CMO services. It has achieved a 99%+ success rate on PPQ batches, ranking among the industry's top performers. Since 2017, it has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners.

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics passed more than 1,800 GMP quality audits led by clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of clients' trust.

Global Layout: Building Strategic Hubs in the U.S., Singapore and Qatar

WuXi Biologics is increasing strategic investments in the U.S. to deliver integrated biologics services. By leveraging cross‑site synergies among facilities in New Jersey and Massachusetts, the company enables the seamless transfer of materials, samples, and products across the U.S..

In Singapore, the company has commenced construction of its new modular drug product facility, while the drug substance modular facility is currently in the design phase. Meanwhile, its subsidiary WuXi XDC achieved mechanical completion of its Singapore manufacturing facility in June 2025, positioning the Singapore site as a strategic hub within the global network.

In December 2025, WuXi Biologics announced the signing of an MOU with the Qatar Free Zones Authority (QFZ). The long-term strategy is to establish the Qatar site as a strategic pillar within WuXi Biologics' global CRDMO network, marking the company's entry into the region while extending its global footprint and capabilities.

Global Leading Digital CRDMO: Powering World-class Speed, Quality, Operational Efficiency and Client Experience

WuXi Biologics has embedded digital innovations into every fabric of research, development, manufacturing, operations and customer engagement that truly redefined values for its partners.

The DaVinci Client Portal provides a secure, real-time interface for proposal generation, access to experimental and manufacturing data and reports, cost estimates, and shipment tracking. Lab core systems, such as BioFoundry and InSilico, accelerate discovery, development and manufacturing by enabling digital twins, in‑silico modeling and predictive decision-making. By leveraging smart manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain and ensured data integrity and high product quality, while advanced planning systems have delivered about a 20% improvement in efficiency. Recently, WuXi Biologics launched the industry-leading digital twin platform PatroLabTM to enhance process performance, minimize process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing.

A Leader in Industry Sustainability

As a participant of the United Nations Global Compact (UNGC), WuXi Biologics has made significant strides in sustainability, earning widespread industry recognition. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP "A List" for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

Sustainable High Growth in 2026

In 2026, WuXi Biologics will build on strong momentum with accelerated growth driven by robust research, leading development and explosive manufacturing business. By putting clients first and leveraging its full end‑to‑end capabilities, WuXi Biologics is fast‑tracking biologics innovation for global clients and delivering meaningful benefits to patients around the world.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media
[email protected]

Business
[email protected]

SOURCE WuXi Biologics

Myriad Genetics, Inc. (MYGN) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 8:15 PM EST

Company Participants

Samraat Raha - President, CEO & Director
Ben Wheeler - CFO & Principal Accounting Officer

Conference Call Participants

Matthew Sykes

Presentation

Unknown Analyst

Good evening, ladies and gentlemen. I'm [ Nischal Kapadia ]. I'm an associate with the Healthcare Investment Banking Group at JPMorgan. It's my pleasure to welcome you to the company presentation for Myriad Genetics. Today, we are joined by Sam Raha, who is the President and CEO at Myriad, who will be taking us through the presentation. And Sam is also joined by Ben Wheeler, who will be joining us for the Q&A. Ben serves as the Chief Financial Officer at Myriad.

Samraat Raha
President, CEO & Director

Thank you very much. Good afternoon, everyone. It's a pleasure to be here and have an opportunity to provide you an update of Myriad what lies ahead. First, forward-looking statements for your pleasure.

So I've been with the company for 2 years now. And from the beginning, I've been inspired by the noble purpose, which is to advance the health and well-being for all. The noble purpose is palpable throughout our organization and a reminder every day how we are making an impact.

A little bit about Myriad. We are a leader in precision medicine and diagnostic testing. We have been a pioneer for over 30 years now since we originally bought BRCA1 testing to make breast cancer, we have over 1,000 publications and counting. We're deeply rooted in science and medicine and in 2025 we served over 55,000 health care providers and delivered over 1.5 million tests, test reports.

Now that being said, we are at a very important inflection point for the company. As we move forward, we're going to build

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Perspective Therapeutics, Inc. (CATX) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 5:15 PM EST

Company Participants

Johan Spoor - CEO & Director

Conference Call Participants

Ben Davis

Presentation

Ben Davis

Hello, everyone, and welcome to the 2026 JPMorgan Healthcare Conference. My name is Ben Davis. I'm an associate with the JPMorgan Healthcare Investment Banking team. And today, I will be introducing Thijs Spoor, Joel Sendik and Marcus Puhlmann, the Perceptive Therapeutics team. And they'll be running through the presentation. Afterwards, we'll have a bit of time for Q&A. We'll be passing around the mic for anyone who has questions. Thank you.

Johan Spoor
CEO & Director

Great. Thanks, Ben, and thank you to JPMorgan for inviting us to present at the conference today. My name is Thijs Spoor, the CEO. I do acknowledge that everything that we put out there is current on the SEC website. We may make some forward-looking statements. We encourage you to look with everything as filed. So I want to tell you first about why I'm in the business and why I like what we do and why I'm really passionate. And it always starts and should end with a patient and what happens to a patient.

So this woman is in her 80s. She had neuroendocrine cancer. So she had these tumors. She was stable on somatostatin for a while. And -- but she had then started to progress. And all these red circles here were tumors that showed up in this woman's abdomen. And so she needed some kind of interventional treatment. And so a woman in her 80s with a tumor with multiple tumors that couldn't just be treated directly. And so we actually treated her with one of our medicines, VMT-alpha-NET. And after the first dose of our drug, we're able to see actually a meaningful reduction in those tumors.

VANCOUVER, BC / ACCESS Newswire / January 14, 2026 / Zimtu Capital Corp. (TSXV:ZC)(FSE:ZCT1) ("Zimtu" or the "Company") announces that its has acquired 2,400,000 shares (the "Shares") of Apex Critical Metals Corp. ("Apex") at a price of $0.06667 per Share pursuant to a Warrant exercise.

Prior to the warrant exercise, Zimtu directly owned and controlled 5,547,216 common shares of Apex representing 7.75% of the issued and outstanding common shares of Apex on a fully diluted basis. Following the warrant exercise, Zimtu holds 7,947,216 common shares in the capital of Apex and 278,336 share purchase warrants, representing 10.87% of the issued and outstanding common shares of Apex, on an undiluted basis, and 7.58% of the issued and outstanding common shares of Apex on a partially diluted basis.

Zimtu acquired the Shares for investment purposes only, and depending on market and other conditions, may from time to time in the future increase or decrease its ownership, control or direction over securities of Apex, through market transactions, private agreements or otherwise.

This acquisition by Zimtu of the 2,400,000 Shares exceeded 2% of the issued and outstanding common shares of Apex and triggered the requirement to file this news release, which is being issued pursuant to the requirements set forth in National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and National Instrument 62-104 - Take-Over Bids and Issuer Bids. Zimtu will be filing an early warning report with respect to the acquisition of the Units containing additional information under Apex's SEDAR+ profile at www.sedarplus.ca.

About Zimtu Capital Corp.
Zimtu Capital Corp. is a public investment issuer that aspires to achieve long-term capital appreciation for its shareholders. Zimtu Capital companies may operate in the fields of mineral exploration, mining, technology, life sciences or investment. The Company trades on the TSX Venture Exchange under the symbol "ZC" and Frankfurt under symbol "ZCT1". For more information, please visit https://www.zimtu.com.

On Behalf of the Board of Directors
ZIMTU CAPITAL CORP.

"Sean Charland"
President & Director
Tel: 604.681.1568

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements, which include any information that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future. Forward-looking statements in this press release include statements that the Company may from time to time increase or decrease its ownership, control or direction over securities of Apex, depending upon market or other conditions and statements; that the Company will file an early warning report respecting the acquisition of the Units; and that the Company aspires to achieve long-term capital appreciation for its shareholders. These statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed, implied by or projected in the forward-looking information or statements. Important factors that could cause actual results to differ from these forward-looking statements include, but are not limited to: risks associated with the business of the Company or the businesses of the companies that the Company has invested in, including, without limitation, the natural resource exploration industry; changes in commodity prices as the Company has investments in natural resource exploration issuers; changes in interest and currency exchange rates; geopolitical risk and social unrest; changes in general economic conditions or conditions in the financial markets; and economic, competitive, governmental, environmental and technological factors which may affect the Company's operations, investments, markets, products and share price. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date of this document or to revise them to reflect the occurrence of future unanticipated events.

SOURCE: Zimtu Capital Corp.

Vistry Group PLC (BVHMY) Q4 2025 Sales/Trading Call January 14, 2026 4:00 AM EST

Company Participants

Gerald Fitzgerald - CEO & Executive Chairman
Timothy Lawlor - CFO & Executive Director

Conference Call Participants

Aynsley Lammin - Investec Bank plc, Research Division
Clyde Lewis - Peel Hunt LLP, Research Division
Rebecca Parker - Goldman Sachs Group, Inc., Research Division
Christopher Millington - Deutsche Bank AG, Research Division
William Jones - Rothschild & Co Redburn, Research Division
Ami Galla - Citigroup Inc., Research Division
Allison Sun - BofA Securities, Research Division
Charlie Campbell - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Operator

Hello, and welcome to this Vistry Trading Update Call. Today, we will hear from Chief Executive Officer, Greg Fitzgerald; and Chief Financial Officer, Tim Lawlor. [Operator Instructions] I'll now hand you over to Greg Fitzgerald. Greg, please go ahead.

Gerald Fitzgerald
CEO & Executive Chairman

Thank you, Oliver, and good morning, everyone, and happy New Year to you all. I'll start with a brief introduction, if I can, before we open the lines for your questions. And as usual, I have Tim Lawlor with me.

So in 2025, we delivered our market expectations with profits ahead of 2024. This required a particularly strong second half performance delivered despite ongoing subdued market demand in the private sales market. This is absolutely a testament to the incredible hard work of the teams, but also a recognition of our differentiated market positioning. We start 2026 in a fundamentally better shape than a year ago, a leaner, more efficient business. The pent-up demand for housing is greater than ever and the affordable market, in particular, should take off in 2026.

We had a well-documented difficult year in 2024, and this required us to stabilize, simplify and reorganize the business in the first half of 2025. These steps were successfully completed and helped

NEW ORLEANS, La., Jan. 14, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE), if they purchased or otherwise acquired the Company’s securities between January 27, 2025 to October 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

Get Help

Alexandria Real Estate Equities investors should visit us at https://claimsfiler.com/cases/nyse-are/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Alexandria and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On October 27, 2025, post-market, the Company disclosed financial results for the third quarter of fiscal year 2025 that were below expectations, including cuts to its FFO guidance for the full-year 2025, due to lower occupancy rates, slower leasing activity and most notably, a real estate impairment charge of $323.9 million with $206 million attributed to its LIC property.

On this news, the price of Alexandria’s shares fell from a closing market price of $77.87 per share on October 27, 2025 to $62.94 per share on October 28, 2025, a decline of about 19% in the span of just a single day.

The case is Warren Hern v. Alexandria Real Estate Equities, Inc., et al., No. 25-cv-11319.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

-

Aiming to transform into an innovative company through diverse knowledge and expertise

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will launch the Talent Mobility System to match employees with jobs in the company’s global group in order to develop, mobilize and engage top talent. It will also revise the Global- On the Job Training (G-OJT) System to provide young employees with deeper overseas work experiences compared to those of conventional overseas temporary-training programs.

Mitsubishi Electric, which employs approximately 150,000 people at more than 200 Group companies around the world, is promoting initiatives that maximize the development, sharing and utilization of knowledge and abilities in its diverse and versatile workforce, as well as the allocation, utilization and development of employees across countries, regions and business sites. The company expects the newly announced systems to accelerate efforts to assign, develop, and utilize employees with diverse knowledge and abilities throughout the Group, with the goal of transforming Mitsubishi Electric into an “innovative company” that creates value with new ideas without fear of risk.

About Talent Mobility System

Mitsubishi Electric promotes the allocation and utilization of employees across countries, regions and business sites, particularly management candidates from overseas Group companies. In many cases, mid-level and young employees of overseas Group companies are only utilized within their respective offices. Through the Talent Mobility System, the company will quickly grasp and share information on top talent throughout the Group, accelerating their development and motivation by creating opportunities for borderless career expansion.

For the full text, please visit: www.MitsubishiElectric.com/news/

More News From Mitsubishi Electric Corporation

Back to Newsroom

Expects 4Q25 consolidated operating income to be $135.0 to $145.0 million Expects 4Q25 net income and diluted EPS to be $131.3 to $146.3 million and $4.22 to $4.70, respectively 4Q25 diluted EPS includes a benefit of approximately $0.77 due to positive income tax adjustments Expects full year 2026 consolidated operating income to approach the level achieved in full year 2025 Repurchased approximately 0.7 million shares in 4Q25 , /PRNewswire/ -- Matson, Inc. ("Matson" or the "Company") (NYSE: MATX) today announces preliminary fourth quarter financial results, provides 2026 outlook for consolidated operating income and announces that its fourth quarter earnings call will be held on February 24, 2026.

Matt Cox, Matson's Chairman and Chief Executive Officer, commented, "Matson had a solid finish to the year with consolidated fourth quarter results that exceeded our expectations. During the quarter, our China service saw higher than expected freight rates and volume driven by strong e-commerce and e-goods demand. Our China service benefited from strong freight demand in our key customer segments as well as a more stable trading environment in the Transpacific tradelane as a result of the U.S.-China trade and economic deal announced on October 30, 2025, which reduced uncertainty regarding tariffs, port entry fees, global trade and other geopolitical factors. Looking ahead, for full year 2026 we expect consolidated operating income to approach the level achieved in full year 2025 based on our expectations of continued solid U.S. consumer demand and a stable trading environment in the Transpacific tradelane."

Mr. Cox added, "For the fourth quarter 2025, we expect consolidated operating income to be $135.0 to $145.0 million. We also expect fourth quarter 2025 net income and diluted EPS to be $131.3 to $146.3 million and $4.22 to $4.70, respectively. Fourth quarter 2025 diluted EPS includes a benefit of approximately $0.77 per share due to positive income tax adjustments. We will provide more details on our fourth quarter and full year 2025 financial performance and 2026 outlook on our earnings call on February 24, 2026."

Fourth Quarter Tradelane Volume (Forty-foot equivalent units (FEU)) (1)(2)(3):

For the three months ended December 31, 2025 compared to the three months ended December 31, 2024 and on a FEU basis: 

Hawaii container volume increased 0.6 percent primarily due to higher general demand; Alaska container volume decreased 3.3 percent primarily due to one less northbound sailing compared to the year ago period, partially offset by higher AAX volume; China container volume was 7.2 percent lower; Guam container volume was 4.4 percent higher primarily due to higher general demand; and Other containers volume increased 11.6 percent.
________________________

(1)

Approximate volume included for the period are based on the voyage departure date, but revenue and operating income are adjusted to reflect the
percentage of revenue and operating income earned during the reporting period for voyages in transit at the end of each reporting period.

(2)

China volume includes containers from China and other Asia origins.

(3)

Other containers includes containers from services in various islands in Micronesia and the South Pacific, and Okinawa, Japan.

Other Items

SSAT Impairment Charge Last Year: In the fourth quarter 2024, operating income, net income and diluted EPS included an impairment charge related to the write-down of a terminal operating lease asset at SSAT, which impacted fourth quarter 2024 operating income, net income and diluted EPS by $18.4 million, $14.0 million and $0.42 per share, respectively. Income Taxes: Income taxes for the fourth quarter 2025 is estimated to be $6.0 to $11.0 million, which implies an effective tax rate for the quarter of 3.9 to 7.7 percent, due to the benefit of positive income tax adjustments. Compared to an effective income tax rate of 22.0 percent, the midpoint of this fourth quarter income taxes range would benefit diluted EPS by approximately $0.77 per share for the quarter. Liquidity and Debt: Matson's cash and cash equivalents as of December 31, 2025 was approximately $141.9 million, which excluded $532.7 million in cash on deposit within the Capital Construction Fund ("CCF"). Total debt as of December 31, 2025 was $361.2 million.(4)  Share Repurchases: During the fourth quarter of 2025, Matson repurchased approximately 0.7 million shares for a total cost of $78.1 million.(5) As of December 31, 2025, the Company had approximately 1.1 million shares remaining in its share repurchase program. A slide presentation that accompanies this press release is available on the Company's website at www.matson.com, under Investors.

(4)     Total debt is presented before any reduction for deferred loan fees as required by GAAP.
(5)     Includes stock repurchased during the quarter but not settled and taxes on share repurchases that will be paid after the quarter end

Teleconference and Webcast

A conference call is scheduled on February 24, 2026 at 4:30 p.m. ET when Matt Cox, Chairman and Chief Executive Officer, and Joel Wine, Executive Vice President and Chief Financial Officer, will discuss Matson's fourth quarter results.

Date of Conference Call:

Tuesday, February 24, 2026

Scheduled Time:

4:30 p.m. ET / 1:30 p.m. PT / 11:30 a.m. HT

The conference call will be broadcast live along with an additional slide presentation on the Company's website at www.matson.com, under Investors. 

Participants may register for the conference call at:

https://register-conf.media-server.com/register/BI2f86b7aed35545c9bacf93a43078cde7

Registered participants will receive the conference call dial-in number and a unique PIN code to access the live event. While not required, it is recommended you join 10 minutes prior to the event starting time. A replay of the conference call will be available approximately two hours after the event by accessing the webcast link at www.matson.com, under Investors.

About the Company

Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services. Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia. Matson also operates premium, expedited services from China to Long Beach, California, which includes transshipment of cargo from other Asia origins, provides service to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia. The Company's fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges. Matson Logistics, established in 1987, extends the geographic reach of Matson's transportation network throughout North America and Asia. Its integrated, logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska. Additional information about the Company is available at www.matson.com.

Forward-Looking Statements

Statements in this news release that are not historical facts are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation those statements regarding outlook; operating income; consumer demand; and the trading environment. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement, including but not limited to risks and uncertainties relating to repeal, invalidation, substantial amendment or waiver of the Jones Act or changes in its application, or the Company were determined not to be a United States citizen under the Jones Act; changes in macroeconomic conditions, geopolitical developments, or governmental policies; our ability to offer a differentiated service in China for which customers are willing to pay a significant premium; new or increased competition; our relationship with customers and vendors and changes in related agreements; fuel prices, our ability to collect fuel-related surcharges and/or the cost or limited availability of required fuels; evolving regulations and stakeholder expectations related to sustainability matters; timely or successful completion of fleet upgrade initiatives; the Company's vessel construction agreements with Philly Shipyard; the occurrence of weather, natural disasters, maritime accidents, spill events and other physical and operating risks; transitional and other risks arising from climate change; actual or threatened health epidemics, outbreaks of disease, pandemics or other major health crises; significant operating agreements and leases that may not be renewed/replaced on favorable or acceptable terms; any unexpected dry-docking or repair costs; joint venture relationships; conducting business in foreign shipping markets, including the imposition of tariffs or a change in international trade policies; any delays or cost overruns related to the modernization of terminals; war, actual or threatened terrorist attacks, efforts to combat terrorism and other acts of violence; consummating and integrating acquisitions; work stoppages or other labor disruptions caused by our unionized workers and other workers or their unions in related industries; loss of key personnel or failure to adequately manage human capital; the use of our information technology and communication systems and cybersecurity attacks; changes in our credit profile, disruptions of the credit markets, changes in interest rates and our future financial performance; our ability to access the debt capital markets; continuation of the Title XI and CCF programs; costs to comply with and liability related to numerous safety, environmental, and other laws and regulations; and disputes, legal and other proceedings and government inquiries or investigations. These forward-looking statements are not guarantees of future performance. This release should be read in conjunction with our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and our other filings with the SEC through the date of this release, which identify important factors that could affect the forward-looking statements in this release. We do not undertake any obligation to update our forward-looking statements.

SOURCE Matson, Inc.

NEW ORLEANS, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT), if they purchased or otherwise acquired the Company’s securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Middle District of Tennessee.

Get Help

Ardent Health investors should visit us at https://claimsfiler.com/cases/nyse-ardt/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Ardent and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On November 12, 2025, post-market, the Company disclosed a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after the Company transitioned to a new revenue accounting system and from purported “recently completed hindsight evaluations of historical collection trends.” The Company further disclosed a cut to 2025 EBITDA guidance of $57.5 million at the midpoint, or about 9.6%, from $575 million – $625 million to $530 million – $555 million due to “persistent industry-wide cost pressures,” including “payer denials,” and also recorded a $54 million increase in professional liability reserves “with respect to recent settlements and ongoing litigation arising from a limited set of claims between 2019 and 2022 in New Mexico” as well as “consideration of broader industry trends, including social inflationary pressures.”

On this news, the price of Ardent’s shares fell $4.75 per share, or nearly 34%, from $14.05 per share on November 12, 2025, to close at $9.30 per share on November 13, 2025, on unusually heavy trading volume.

The case is Postiwala v. Ardent Health, Inc., et al., No. 26-cv-00022.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Item 1 of 2 A woman checks her mobile phone inside the premises of the Supreme Court in New Delhi, India, September 28, 2018. REUTERS/Anushree Fadnavis/File Photo

[1/2]A woman checks her mobile phone inside the premises of the Supreme Court in New Delhi, India, September 28, 2018. REUTERS/Anushree Fadnavis/File Photo Purchase Licensing Rights, opens new tab

NEW DELHI, Jan 15 (Reuters) - India's top court is set to rule on Thursday if taxes should be levied on U.S. investment firm Tiger Global's $1.6 billion stake sale in Flipkart to Walmart (WMT.O), opens new tab in 2018, in what could be a landmark ruling on international tax-treaty use by firms.

Keenly watched by foreign investors, the legal dispute relates to how Tiger Global used the India–Mauritius tax treaty to claim tax exemptions and New Delhi's fierce objections to it. The ruling will have implications for how India applies tax principles in cross-border deals.

Sign up here.

"The ruling is likely to redefine the treaty interpretation law," said Mukesh Butani, managing partner of Indian law firm BMR Legal, which advises clients on international tax laws and treaties.

Tiger Global and Indian tax authorities have been locked in a legal tussle over its 2018 stake sale in Indian e-commerce company Flipkart to Walmart worth 144.4 billion rupees ($1.6 billion). The deal was part of the U.S. retail company's $16 billion acquisition of Flipkart that year.

The stake sold at the time, 17% according to local media reports, was held by Tiger Global's units in Mauritius.

While Indian tax authorities argued Tiger Global wrongly used the India-Mauritius tax avoidance treaty to not pay any tax on its profits, the investment firm argued it can do so as the treaty exempted such a transaction.

The tax authorities say the Tiger Global Mauritius units served merely as a conduit for Tiger Global U.S. - a description the investment firm says is incorrect.

The Supreme Court has been hearing the case since January 2025 as Indian tax authorities challenged a previous Delhi High Court ruling that was in favour of Tiger Global and found no wrongdoing.

Walmart competes with Amazon (AMZN.O), opens new tab in India's thriving e-commerce market, where online shopping has boomed in recent years. Walmart has previously not commented on the matter.

Reporting by Arpan Chaturvedi and Aditya Kalra; Editing by Muralikumar Anantharaman

Our Standards: The Thomson Reuters Trust Principles., opens new tab

NEW ORLEANS, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Sprouts Farmers Market, Inc. (“Sprouts” or the “Company”) (NasdaqGS: SFM), if they purchased or otherwise acquired the Company’s securities between June 4, 2025 and October 29, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Arizona.

Get Help

Sprouts investors should visit us at https://claimsfiler.com/cases/nasdaq-sfm-2/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Sprouts and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On October 29, 2025, the Company announced its third quarter fiscal 2025 results, disclosing comparable stores sales growth below expectations as well as disappointing fourth quarter guidance and cuts to its full year estimates, despite raising them only one quarter prior, due to “challenging year-on-year comparisons as well as signs of a softening consumer.”

On this news, the price of Sprouts’ shares fell from a closing market price of $104.55 per share on October 29, 2025 to $77.25 per share on October 30, 2025, a decline of about 26.11% in the span of just a single day.

The case is Singh Family Revocable Trust u/a dtd 02/18/2019 v. Sprouts Farmers Market, Inc., et al., No. 25-cv-04416.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Novavax, Inc. (NVAX) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 7:30 PM EST

Company Participants

John Jacobs - President, CEO & Director
Ruxandra Draghia-Akli - Executive VP and Head of Research & Development
James Kelly - Executive VP, CFO & Treasurer

Conference Call Participants

Anupam Rama - JPMorgan Chase & Co, Research Division

Presentation

Anupam Rama
JPMorgan Chase & Co, Research Division

All right. Let's go ahead and get started. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, Joyce Tso and Rati Pinhe. Our next presenting company is Novavax. And presenting on behalf of the company, we have CEO, John Jacobs.

John Jacobs
President, CEO & Director

Thanks, everyone. Welcome, and thanks for joining us to kick off 2026 at JPM. I'm John Jacobs, the CEO of Novavax. Before we get started, I just want to remind everyone, we'll be making forward-looking statements. So please review our SEC filings and disclaimers in the slide deck to make sure you get a good handle on the risk factors for the company before we present. Thank you.

So our first slide says this is Novavax. And what's on there is a vision statement. And I know pretty much every company has a vision statement and a mission statement. We've all been through helping to build them and seeing them. But this particular vision statement has a real meaning to me, to our employees, and I think to almost all of us in biotech, if not all of us. My kids ask me as they're growing up and finishing college, dad, why did you pick health care? Why did you pick biotech as a career? Now we could pick anything. If you want a career that's super exciting, ups and downs of

NEW ORLEANS, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against CoreWeave, Inc. (NasdaqGS: CRWV), if they purchased or otherwise acquired the Company’s securities between March 28, 2025 and December 15, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

Get Help

CoreWeave investors should visit us at https://claimsfiler.com/cases/nasdaq-crwv/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

CoreWeave and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had overstated its ability to meet customer demand for its service; (ii) the Company materially understated the scope and severity of the risk that its reliance on a single third-party data center supplier created for its ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company’s revenue; and (iv) as a result, CoreWeave's public statements were materially false and misleading at all relevant times.

The case is Masaitis v. CoreWeave, Inc., et al., No. 26-cv-00355.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

Monero Price Hits All-Time High After a 60% Breakout, Here’s WhyMonero hit a new all-time high near $800 as investors rushed into privacy-focused crypto.Global crackdowns and stricter KYC rules boosted demand for anonymous transactions.The US CLARITY Act changes, which expands surveillance and reporting rules, added to fears about on-chain transparency.Monero (XMR) climbed to a new all-time high on Wednesday, breaking above the $797 mark as investors piled into privacy-focused cryptocurrencies. The move capped a week-long rally that lifted XMR by more than 50%, making it one of the strongest performers in the crypto market.

The surge pushed Monero’s market value above $13 billion and briefly placed it among the top 15 cryptocurrencies by market cap. Trading volumes also spiked as buyers rushed to gain exposure.

Sponsored

Sponsored

Rising Demand for Financial PrivacyThe main driver behind the rally is a sharp rise in demand for financial privacy. Across major markets, regulators are tightening KYC and anti-money-laundering rules. That has made it harder to transact anonymously on most blockchains.

As a result, more users are turning to coins that hide wallet balances, transaction amounts, and sender identities. Monero remains the largest and most battle-tested option in that category. 

Monero All-Time High Near $800 on January 14. Source: CoinGeckoParadoxically, bans and restrictions have fueled the rally rather than stopped it.

Earlier this week, Dubai’s financial regulator barred exchanges in the Dubai International Financial Centre from listing or promoting privacy coins. 

Also, the European Union is preparing rules that would ban anonymous crypto accounts and privacy tokens from 2027.

Instead of killing demand, those moves triggered front-running behavior. Investors rushed to buy privacy assets before access becomes more limited.

Sponsored

Sponsored

Monero is pumping with no etf, no major exchanges, no michael saylor, no government strategic reserves

just a community of people who love freedom

— Crypto Tea (@Cryptotea) January 12, 2026
Capital Rotated Out of ZcashMonero also benefited from turmoil inside the Zcash ecosystem.

Zcash, its closest privacy-coin rival, lost momentum after governance disputes and the departure of its core development team. 

As confidence faded, traders rotated capital into Monero, which is viewed as more decentralized and less dependent on a single foundation.

Sponsored

Sponsored

That shift added fuel to XMR’s breakout.

Monero also cleared multi-year resistance levels on the charts. Once it broke above the $600–$650 range, systematic traders and momentum funds joined the move.

Social media interest spiked, and liquidity followed. That created a feedback loop of buying that pushed prices toward $700.

CLARITY Act Drama Fueled the RallyUS crypto policy debates may also be helping the privacy narrative.

Sponsored

Sponsored

The Senate’s rewrite of the CLARITY Act would expand financial surveillance, strengthen reporting requirements, and give regulators broader access to transaction data across exchanges and DeFi platforms. 

The CLARITY Act just changed. The Senate amendment adds more SEC power, more disclosures, tighter stablecoin rules, and DeFi oversight.

Coinbase has already opposed this version ❌ pic.twitter.com/XH0RB3XN7w

— BeInCrypto (@beincrypto) January 14, 2026 While the bill does not target privacy coins directly, it reinforces fears that on-chain activity will become more visible to governments.

That environment makes privacy-preserving assets more attractive, even for users who are not engaged in illicit activity.

Monero now faces heavy technical resistance near $700. Short-term pullbacks are likely after such a sharp move.

Still, the underlying trend is clear. As governments tighten oversight and restrict anonymity, demand for financial privacy is rising. For now, Monero remains the market’s main beneficiary.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Journalist

Posted: January 15, 2026

To gauge what’s next, it helps to look back at recent moves.

Notably, the crypto market kicked off the third week of this month with solid momentum, lifting the TOTAL market cap 4.45%, or roughly $130 billion in one swing, putting risk assets back in the green.

Naturally, Bitcoin [BTC] followed, climbing 5% to $95k, pushing its market cap over $1.9 trillion. However, looking closer, that accounts for roughly 61% of total market flows, underscoring that the rally was “BTC-led.”

Source: TradingView (BTC MARKET CAP)

Moreover, Bitcoin’s move wasn’t random. Instead, “stability” across the U.S. economy appears to have triggered the surge. As AMBCrypto noted, CPI came in exactly in line with estimates at 2.7% YoY.

Meanwhile, core CPI came in at 2.6% YoY (vs. 2.7% expected), marking the lowest reading in nearly five years. In essence, this points to a stabilizing inflation backdrop. However, the story didn’t end there.

Earlier this month, rate-cut odds had slipped as Fed Chair Jerome Powell reinforced a hawkish stance. Yet, this latest CPI release has clearly put him under pressure, making it one of several catalysts driving Bitcoin’s rally.

Macro confidence builds as Bitcoin sets its sights on $100k This post-CPI rally could mark a turning point for Bitcoin.

According to AMBCrypto, the move underscores how macro catalysts continue to drive flows. Against this setup, progress on the CLARITY and GENIUS Acts, combined with cooling inflation and a softening labor market, could help extend the current momentum.

In fact, Matt Mena, Crypto Research Strategist at 21Shares, is projecting a near-term $100k target, with Bitcoin’s 5% move reinforcing its role as a market “hedge” amid ongoing geopolitical pressure on the global economy.

“Looking ahead, several catalysts could push Bitcoin toward $100k. Cooling inflation and stable jobs data support the case for rate cuts this year.”

He added,

“On the news, Bitcoin broke above $92k and is now consolidating near that level. Increasingly, Bitcoin is being viewed as a macro hedge amid rising geopolitical tensions.”

Backing this thesis, the move is being led by spot demand, not leverage. 

Put simply, Bitcoin investors appear to be positioning ahead of a bull run.

In this setup, $95k looks less like a top and more like a base that could serve as a springboard toward six figures, driven primarily by macro tailwinds.

Final Thoughts Bitcoin’s move to $95k drove roughly 61% of total market flows, highlighting a spot-led rally amid stabilizing inflation and macro confidence. Macro catalysts (including cooling CPI, softening labor data, and progress on the CLARITY and GENIUS Acts) position BTC for a potential breakout toward $100k.

Ritika Gupta is a Financial Journalist and Geopolitical Analyst at AMBCrypto, specializing in the critical intersection of world politics, economic policy, and the cryptocurrency markets. Her analysis is informed by her distinguished background, which includes professional experience at major news network. She holds a Bachelor's degree in Political Science and Psychology from Gargi College, University of Delhi. This academic training provides her with a sophisticated framework for dissecting complex issues such as international regulations, government fiscal policies, and the geopolitical forces that directly influence asset valuations. At AMBCrypto, Ritika applies this expert lens to synthesize macroeconomic data and political developments, offering readers a deeper context for market movements. She excels at explaining not just what is happening in the market, but why it is happening. Her work is dedicated to providing strategic insights that empower readers to understand the complex relationship between global events and their digital assets.

TLDR

BonkFun launches “BONK Classic” model Zero creator fees and swap fees of only 0.30%. Market Recovery The platform aims to reclaim dominance from Pump.fun through a liquidity-first structure. Volume Surge BONK’s trading volume increased by 86% following the announcement, surpassing $300 million daily. BonkFun has taken a significant step by eliminating creator fees in its new “BONK Classic” model, designed to revitalize memecoin launches on Solana. This move seeks to correct the misalignment of interests between developers and traders by removing creator revenue generated from trading activity.

Everyone agrees creator fees are too damn high!

Today is the first step in bringing the trenches more in line. First, we are introducing BONK Classic launches. BONK Classic launches are an opportunity to bring the trenches back to their former glory.

– NO creator fees
– 0.30%… pic.twitter.com/zqtxzpr07T

— BONK.fun (@bonkfun) January 14, 2026 By doing so, BonkFun prioritizes liquidity depth over individual profits, facilitating smoother price action and significantly reducing slippage.

This shift comes during a period of intense competition, where cost efficiency is a deciding factor in attracting volume. By lowering swap fees to 0.30%, BonkFun emulates the conditions that allowed several memecoin launches to reach billion-dollar valuations over the past year. Consequently, the BONK ecosystem expects this transparency and cost-saving approach to win back users who had migrated to competing platforms.

Innovation and Competition Against Pump.fun’s Dominance Beyond the free model, the platform retains its “BONKERS” option for projects requiring customized economic structures, allowing reward payouts in stablecoins. However, the pressure remains high; competitors like Pump.fun have reclaimed leadership, processing nearly 30,000 new launches every 24 hours.

Analysts view these new fees as vital for BonkFun to recover the 55% market share it held during its peak.

The market response has been definitive, resulting in an 86% surge in BONK token trading volume. This renewed interest suggests that market participants value platforms that lower entry barriers for new memecoin launches.

In summary, the “fee war” among Solana launchpads is far from over. BonkFun is now positioning itself with one of the most affordable, community-centric offerings in the entire crypto sector.

Ripple moved closer to Europe's regulated payments core after securing preliminary approval for a Luxembourg electronic money license, strengthening its ability to scale compliant, blockchain-powered cross-border payments across the EU's financial system. Ripple Advances Toward EU Payments Core After Regulatory License Green Light A major step toward deeper regulatory integration unfolded in Europe's financial sector.

The Sui blockchain, a rapidly growing cryptocurrency network for sending and receiving transactions, has been restored and is now operational after nearly six hours of downtime. The outage that began in the afternoon halted transactions and froze over $1 billion in value on the network. 

The Sui Foundation, the blockchain’s organization, acknowledged the problem at 3:24 p.m. UTC on X and reassured users that core developers were currently working to resolve the issue. “The Sui network is now back and fully operational. Transactions are flowing normally. If you continue to experience issues, please refresh your app or browser window. Thanks for your patience. We will share a full incident review in the coming days,” the Foundation said.

According to the Foundation, the team began investigating the problem at 2:52 pm UTC and resolved it at 8:44 pm UTC, restoring the network after 5 hours and 52 minutes. The outage was described as a “Consensus outage,” a technical issue that prevents the blockchain from confirming transactions. The Foundation has not yet explained what caused the problem.

Sui is a Layer 1 network developed primarily by Mysten Labs, a team spun out of Meta’s canceled Diem stablecoin and wallet project, similar to rival high-throughput networks like Aptos. The network has reportedly seen steady growth and investor interest, having surpassed $10 billion in 30-day DEX volume around the time 21 Shares announced its intention to launch a leveraged ETF tracking its native token.

Sui faces its second major outage The incident on Wednesday is the second severe outage of the Sui network since it began operating in May 2023. The first occurred in November 2024, when the high-speed blockchain developed challenges over time. 

Other networks, such as Solana, have faced comparable issues in the past. Solana has not experienced outages in the last 18 months, at least in part due to emergency updates that enable validators – computers responsible for maintaining the network – to engage in more effective communication and address critical issues more quickly.

Blockchain outages may include 51% attacks, technical errors, and other issues. A typical error occurs in this case, as nodes, i.e., individual entities responsible for processing transactions, are unable to synchronize with each other, resulting in the blockchain becoming offline.

Software bugs may be another error vector, where outdated code can render the network’s processes inoperable. Just last week, Solana’s status account on X urged validators to upgrade to a new version featuring a “critical set of patches.” Updates like these are made to prevent downtime and ensure seamless transaction continuity. Even high-speed blockchains are vulnerable to technical failures, as the comparison suggests, so preventive maintenance can help avoid such scenarios.

In a related development, Ethereum co-founder Vitalik Buterin has recently suggested that decentralized applications (DApps) could help address recurring issues with internet infrastructure. Citing events like the major Cloudflare outage in November, he emphasized the need to strengthen and stabilize online systems.

Following these ongoing issues with internet infrastructure, Buterin shared an X post dated Thursday, January 1, arguing that Ethereum needs to put in extra effort to attain its goal of developing the world computer, which functions as a key infrastructure piece of a freer and open internet.

Afterwards, he asserted that this strategy starts with DApps that carry out their activities without fraud, censorship, or interference from third parties. Ethereum’s co-founder also noted that DApps can be broadly utilized on the blockchain.

Sui token surges briefly during network issue Sui’s native token, SUI, held roughly the same throughout the outage. CoinGecko data showed that the token’s price jumped by 4% upon news of the network issue, before returning to around $1.84.

Market reactions to the outage and subsequent service recovery may have triggered the temporary spike. Despite the pause in transactions, investor and user confidence in the network is not only indicative of the increasing acceptance but also indicates the rapidity with which the Sui team was able to resolve the problem.

The Sui Foundation is still investigating the root cause of the “Consensus outage,” but users can now resume normal activity on the network.

The smartest crypto minds already read our newsletter. Want in? Join them.

TLDR:

XRP received $45 million in weekly inflows, marking a 400% increase compared to the previous week. The asset maintains its support above $2 despite the overall bearish trend in the crypto market. Analysts project targets of up to $3 if the price successfully consolidates above the $2.40 resistance level. XRP began 2026 by reclaiming a bullish position above its 50-day simple moving average. This recovery coincides with a retest of the downtrend—a structure that typically precedes price increases if demand persists. However, the most notable factor is that this firmness appears to be directly supported by institutional investment inflows into XRP.

With $454 million in outflows, this has been the worst week for the global digital asset market since mid-2023; nevertheless, XRP took a different path. Data from CoinShares reveals that institutional investment inflows into XRP reached $45 million weekly, representing growth of over 400% compared to the previous seven days.

Volume Analysis and Market Projections for XRP While institutional optimism is at its peak, data from CryptoQuant suggests that trading activity remains within a neutral and balanced range. This means the current price is not being driven by excessive speculation, but rather by steady institutional investment inflows into XRP during accumulation phases. Consequently, buyers and sellers are currently in equilibrium.

Regarding the technical aspect, analysts agree that the $2.40 zone is the critical level to overcome to confirm a daily trend reversal. Although whale sales totaling $100 million were recently recorded, the maintenance of support suggests that the institutional investment inflows into XRP could push the price toward more ambitious targets near $3.

In summary, XRP’s ability to ignore the “red trend” of the rest of the market underscores its current financial maturity. If large investors maintain their confidence and buying volume stabilizes, the ecosystem could witness a definitive breakout, consolidating the cryptocurrency as the leading asset of the first quarter.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

After months of steady declines and fading enthusiasm, Dogecoin (DOGE) is showing signs of renewed life. The meme-based cryptocurrency has recently stabilized near the $0.14–$0.15 range, breaking out of a short-term downtrend and attracting fresh speculative interest.

Related Reading: Crypto Users Hit By 1,400% Surge In Impersonation Scams, Research Shows

While broader crypto markets remain mixed, DOGE’s price action suggests that selling pressure has eased, creating room for short-term momentum to build.

Dogecoin is trading around $0.148, supported by higher trading volumes and improving technical indicators. The move comes as traders rotate into high-beta assets, such as meme coins, particularly when Bitcoin trades sideways, and macro catalysts are limited.

DOGE's price records some gains on the daily chart. Source: DOGEUSD on Tradingview Selling Pressure Eases as Dogecoin Price Finds Support Dogecoin’s recent stabilization follows a prolonged selloff from October highs, which pushed the price toward the $0.13 zone. That decline flushed out leveraged positions and cooled speculative activity.

In recent sessions, however, DOGE has reclaimed short-term support near $0.14 and briefly touched $0.147, signaling a slowdown in aggressive downside momentum.

On the daily chart, the price remains below key long-term moving averages, indicating a cautious broader trend. Still, DOGE has moved back above its 20-day and 50-day averages, levels many short-term traders watch for early signs of trend shifts.

Momentum indicators also point to stabilization. The RSI has climbed from oversold territory into neutral levels, suggesting buyers are returning without pushing the market into overheated conditions. While spot outflows continue, derivatives data show rising open interest, indicating traders are positioning for near-term volatility.

Speculative Interest Returns to Meme Coins The recent rally is not limited to Dogecoin. Other meme tokens, including Pepe, have also posted sharp gains, reflecting a broader return of speculative appetite. CoinGecko’s GMCI Meme Index has climbed in tandem with rising trading volumes, suggesting the move is driven by active participation rather than thin liquidity.

Investors note that meme coins often outperform when Bitcoin trades within a range, and traders seek faster-moving opportunities. DOGE’s breakout above a weeks-long descending trendline has shifted short-term bias in favor of buyers.

Holding above the $0.138–$0.140 area maintains the rebound, with $0.15 serving as the next key level of resistance. A sustained move above $0.15–$0.155 could open the door to a test of the declining 50-day average near $0.16. Failure to hold current levels, however, would likely send the price back toward the $0.13 base.

New Catalysts: Japan Expansion and Spot ETF Beyond technical factors, potential ecosystem developments are adding to Dogecoin’s visibility.

Discussions around expanding DOGE-related initiatives in Japan, focused on real-world asset tokenization and regulated Web3 applications, highlight growing interest in compliant blockchain use cases within a tightly regulated market.

Related Reading: Ripple Calls XRPL Permissioned Domains A ‘Gamechanger’ As Go-Live Nears

In the U.S., a proposed spot Dogecoin ETF from 21Shares is also drawing attention. If launched, the product would track DOGE’s spot price without leverage or derivatives, giving traditional investors a regulated way to gain exposure. While ETF inflows are not guaranteed, the listing itself could increase market participation and liquidity.

Cover image from ChatGPT, DOGEUSD chart from Tradingview

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

XRP holds a pivotal support zone as price steadies after a pullback, with tightening volatility, neutral momentum signals, and Ripple's expanding European regulatory approvals reinforcing confidence that consolidation may be setting the stage for the next directional move. XRP Consolidates as Ripple Secures New Key Regulatory Approval At 8:30 p.m. on Jan.

HomeStock IdeasLong IdeasIndustrial 

SummaryV2X has outperformed peers, gaining 20% year-to-date, driven by defense budget optimism despite its lower-margin mission-support business model.VVX margins remain around 7%, constrained by cost-plus contracts, with limited near-term benefit from higher defense spending but potential long-term volume growth.I raise my base case price target to $80.70 (from $67.45), reflecting a 2026 valuation window and stable EBITDA growth, despite lower free cash flow estimates.VVX maintains a buy rating, supported by fair valuation on 2025 earnings, a $100M buyback, growing cash, and sub-2x leverage enabling future capital deployment.Looking for a helping hand in the market? Members of The Aerospace Forum get exclusive ideas and guidance to navigate any climate. Learn More » Devrimb/iStock via Getty Images

V2X (VVX) had a strong start to the year, gaining more than 20% on the back of a possible $1.5 trillion defense budget. The stock is now up 13.5% since my last report, outperforming the S&P 500’s 9.3% gain. In this

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Esperion Therapeutics, Inc. (ESPR) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 5:15 PM EST

Company Participants

Sheldon Koenig - President, CEO & Director

Conference Call Participants

Jessica Fye - JPMorgan Chase & Co, Research Division

Presentation

Jessica Fye
JPMorgan Chase & Co, Research Division

Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Esperion. So first, you're going to hear a presentation from the company, and then we're going to have a Q&A session after that. So for everyone in the room, when you have a question, just raise your hand so someone can bring you a microphone for the webcast. And if you're listening online, you can submit questions on the portal. I can ask them up here.

So with that, let me pass it over to Esperion's CEO, Sheldon Koenig.

Sheldon Koenig
President, CEO & Director

Great. Thank you, Jess, and good afternoon, everyone. On behalf of Esperion and all the employees that work there, it's always a privilege to be here at the JPMorgan Conference and really appreciate the time to talk about our Vision 2040. And really, what it's about is executing today while building for tomorrow. So what has got us here, first, forward-looking statements. I won't read all of these, but they're on our website, should you want to read them.

Esperion at a glance. Right now, as you know, we're commercializing NEXLETOL, which is bempedoic acid and NEXLIZET, bempedoic acid plus ezetimibe. We're in a very strong financial position. We hope to reach sustainable profitability in 2026. We have durable cash flows, a strong balance sheet and a very attractive P&L profile. Our partnerships and pipelines will dive into deeper in this presentation. As you know, we are working on the triple combination. I'll cover that in